Nikolas Iosif

Dr. Nikolas Iosif

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
MMMarios Markantonis
Marios Markantonis
PGPanos Georghiou
Panos Georghiou
FTFilippos Triposkiadis
Filippos Triposkiadis
AGAmalia Georgiou
Amalia Georgiou
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Postoperative atrial fibrillation (POAF) is the most frequent post-cardiac surgical arrhythmia and is associated with haemodynamic instability, longer hospital stays, higher healthcare utilisation, stroke and adverse long-term outcomes. Conventional models of POAF focus on advancing age, pre-existing atrial substrate, increasing operative complexity, inflammatory responses related to cardiopulmonary bypass, disturbances in autonomic balance, and acute metabolic insults during the perioperative period. Although these explanations are important, they may be incomplete. Malignancy and the cancer-associated systemic environment involve biological processes potentially relevant to postoperative atrial vulnerability, such as chronic inflammation, oxidative stress, impaired vascular function, hypercoagulability, altered immune response, frailty, and treatment-related myocardial, pericardial, or conduction-system injury. This review assesses whether malignancy should be regarded as an underrecognised modifier of susceptibility rather than as a coincidental comorbidity. Most available data are extrapolated from cardio-oncology and thoracic oncology studies or general studies related to atrial fibrillation (AF) rather than studies focused on cardiac surgery. While malignancy cannot be dismissed as irrelevant to the generation of POAF, it also does not permit causal inference. Future studies should move beyond binary cancer status and incorporate cancer activity, treatment exposures, biomarker profiles, and atrial substrate measures to determine whether malignancy improves perioperative POAF risk stratification.

27 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
PGPanos Georghiou
Panos Georghiou
AGAmalia Georgiou
Amalia Georgiou
NINikolas Iosif
Nikolas Iosif
FTFilippos Triposkiadis
Filippos Triposkiadis
Cardiovascular disease remains Europe’s leading cause of death and disability despite mature evidence for prevention, acute and chronic treatment, rehabilitation, and secondary prevention. This structured critical narrative review evaluates whether the European Safe Hearts Plan can convert this evidence into coordinated, measurable, and accountable cardiovascular pathways. We appraise the plan’s ten flagship actions by evidence maturity and implementation readiness; distinguish shared system functions from disease-specific delivery for acute coronary syndromes, heart failure, and atrial fibrillation; compare selected European Society of Cardiology and American Heart Association/American College of Cardiology recommendations; and propose a core indicator set and staged Cyprus pilot. Guideline-supported interventions should be standardised and audited, whereas screening technologies, digital health, artificial intelligence, and novel phenotyping require governed implementation and prospective assessment of patient outcomes, costs, equity, and unintended consequences. Cyprus is presented as a bounded implementation setting rather than a directly generalisable European model. The plan should be judged through a limited set of clinical, implementation, and equity indicators, including premature cardiovascular mortality, risk factor control, guideline-directed therapy, rehabilitation participation, registry completeness, reach, and fidelity.

Verified
Journal Article
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
KSKlitia Socratous
Klitia Socratous
Sotiris KyriakouSotiris Kyriakou
Sotiris Kyriakou
KLKonstantinos Lampropoulos
Konstantinos Lampropoulos
PGPanos Georghiou
Panos Georghiou
FTFilippos Triposkiadis
Filippos Triposkiadis
Aortitis—inflammation of the aortic wall—presents at the interface of vasculitis, infection, structural aortic disease, and cardiovascular risk. It may occur in giant cell arteritis (GCA), Takayasu arteritis, immunoglobulin G4 (IgG4)-related disease, drug-induced injury, infection, or as an isolated finding after aortic surgery. Modern imaging detects aortic inflammation more frequently, but the main challenge is classification rather than detection: determining whether disease is infectious or immune-mediated, active or dominated by fixed structural damage, systemic or isolated, and whether the dominant threat is aneurysm, dissection, undertreated infection, or avoidable immunosuppression. This review considers aortitis as a high-risk vascular syndrome requiring aetiology-first classification rather than descriptive labelling. Before escalating immunosuppression, infection must be actively excluded and inflammatory activity distinguished from fixed vascular damage. Treatment should be individualised according to phenotype, age, vascular territory, comorbidity, and toxicity risk, with surveillance continuing even after symptoms and inflammatory markers improve. Optimal care depends on multidisciplinary assessment integrating rheumatology, infectious diseases, vascular surgery, radiology, and cardiology expertise. Progress will require standardised imaging definitions, registries linking inflammatory control with structural vascular outcomes, and validation of artificial intelligence (AI) tools before clinical adoption.

27 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Georgios P. GeorghiouGeorgios P. Georghiou
Georgios P. Georghiou
SKSotiris Kyriakou
Sotiris Kyriakou
PGPanos Georghiou
Panos Georghiou
AGAmalia Georgiou
Amalia Georgiou
NINikolas Iosif
Nikolas Iosif
FTFilippos Triposkiadis
Filippos Triposkiadis
Cardiovascular disease remains Europe’s leading cause of death and disability despite strong evidence for prevention, risk-factor treatment, early detection, rehabilitation, and secondary prevention. This critical narrative review evaluates the European Safe Hearts Plan as a proposed framework for organising cardiovascular care and policy. Its value will depend on whether European priorities can be converted into national plans, dedicated financing, primary-care risk assessment, specialist pathways, rehabilitation, interoper-able registries, digital governance, and equity monitoring. We synthesise evidence from clinical guidelines, epidemiological and economic studies, screening trials, rehabilitation research, digital-health and artificial intelligence literature, registry initiatives, envi-ronmental cardiovascular evidence, and implementation-science frameworks. The central challenge is not a lack of effective interventions but their uneven organisation across health systems. Established interventions should be standardised and audited, whereas screening technologies, artificial intelligence, precision medicine, and digital follow-up require governed implementation and prospective evaluation. Cyprus is discussed as a bounded test setting because its universal coverage, national scale, developing digital infrastructure, and academic-clinical links could make feasibility, adoption, costs, equity effects, and transferability observable before wider European adaptation. The Plan should ultimately be judged by measurable improvements in cardiovascular delivery, equity, rehabilitation, data quality, and outcomes, rather than by endorsement alone.